Impact of safer supply programs on injection practices: client and provider experiences in Ontario, Canada

M Gagnon, K Rudzinski, A Guta, RA Schmidt… - Harm Reduction …, 2023 - Springer
Objectives Fentanyl has contributed to a sharp rise in the toxicity of the unregulated drug
supply and fatal overdoses in Canada. It has also changed injection practices. Injection …

Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: results from a global values and preferences survey

M Di Ciaccio, V Villes, C Perfect, JL El Kaim… - Harm Reduction …, 2023 - Springer
Background To inform the development of updated World Health Organization (WHO)
guidelines on simplified service delivery for HCV infection, a global survey was undertaken …

“Apparently, you can only be treated once”: A qualitative study exploring perceptions of hepatitis C and access to treatment among people who inject drugs visiting a …

G Fontaine, J Presseau, J Bruneau, AM Patey… - International Journal of …, 2023 - Elsevier
Background Access to hepatitis C care within harm reduction community organizations for
people who inject drugs is crucial for achieving hepatitis C elimination. However, there is a …

Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who …

EJ Austin, AJ Gojic, EP Bhatraju, KA Pierce… - International Journal of …, 2023 - Elsevier
Abstract Background Direct-acting antivirals (DAAs) offer an unprecedented opportunity to
eliminate hepatitis C virus (HCV) infection, yet barriers among people who inject drugs …

[HTML][HTML] Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs

JI Tsui, AJ Gojic, KA Pierce, EL Tung… - Drug and Alcohol …, 2024 - Elsevier
Background People who inject drugs (PWID) are a key population for treatment with direct-
acting antiviral medications (DAAs) to eliminate hepatitis C virus (HCV). We developed a …

[HTML][HTML] Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study

AD Marshall, J Rance, GJ Dore, J Grebely… - International Journal of …, 2024 - Elsevier
Background Women who inject drugs are significantly less likely to initiate hepatitis C virus
(HCV) treatment than men. Concerted efforts are needed to minimise gender-based …

Subspecialty physicians' perspectives on barriers and facilitators of hepatitis C treatment: a qualitative study

E Bredenberg, C Callister, A Dafoe, BD Holliman… - Harm Reduction …, 2024 - Springer
Introduction The hepatitis C virus (HCV) causes chronic and curable disease with a
substantial burden of morbidity and mortality across the globe. In the United States (US) and …

Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy: a retrospective review of medical …

M Häkkinen, J Tourunen, T Pitkänen, K Simojoki… - … , Prevention, and Policy, 2022 - Springer
Abstract Background Hepatitis C virus (HCV) is common among individuals in opioid agonist
therapy (OAT). HCV treatment has previously been unavailable for most HCV positive OAT …

[PDF][PDF] Interventions for Impact: Studies on Improving Care for People at Risk of Hepatitis C Virus Infection

C Byrne - 2022 - discovery.dundee.ac.uk
The World Health Organization (WHO) estimates that approximately 37 million people are
living with HIV (PLHIV) globally; of these, 2.9 million are co-infected with hepatitis C virus …

Eliminating hepatitis C among priority populations: dynamic transmission modeling studies to inform health policy

C Laniece - 2022 - escholarship.mcgill.ca
Background: Hepatitis C virus (HCV) spreads via unsterile injection materials, or, less
efficiently, via sexual practices. Of 250,000 people living with HCV in Canada, 21,000 are …